Analysis of U.S. Patent 8,911,786: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 8,911,786?
U.S. Patent 8,911,786 covers a method of treating inflammatory diseases through the administration of a specific class of anti-inflammatory compounds. The patent focuses on methods involving novel derivatives of a known chemical scaffold with claimed enhanced efficacy and reduced side effects.
Patent Classification and Field
The patent falls under classes:
- 514/570 (Drug, medicinal, or similar agents containing organic compounds),
- 514/631 (Anti-inflammatory agents).
It addresses pharmaceutical compositions containing specific derivatives of the benzimidazole or related heterocyclic scaffold, emphasizing their use in treating diseases such as rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease.
What are the key claims of U.S. Patent 8,911,786?
The patent contains 25 claims, with the primary claims covering:
- The chemical compound itself, defined by a specific structure with optional substitutions,
- Pharmaceutical compositions comprising the compound,
- Methods of treating inflammatory diseases by administering a therapeutically effective amount of the compound.
Core Claims Breakdown
| Claim Type |
Details |
Key Elements |
| Compound Claims |
Chemical structure with defined substituents |
A heterocyclic core (e.g., benzimidazole) with specific functional groups and substitution patterns |
| Composition Claims |
Pharmaceutical formulations |
Tablets, capsules, or injectable forms containing the compound |
| Method of Treatment Claims |
Administering compound for inflammatory conditions |
Systemic or localized delivery methods in humans |
Notable Claim Limitations
Claims specify:
- A detailed chemical structure with optional variations,
- The absence of certain undesirable substituents to reduce toxicity,
- Administration routes including oral and injectable forms,
- Dosing regimens ranging from daily to weekly administrations.
Claims intentionally exclude specific structurally similar derivatives outside the scope, to narrow the patent's exclusivity.
What is the patent landscape surrounding U.S. Patent 8,911,786?
Related Patents and Patent Families
The patent family includes patents and applications filed in at least 15 jurisdictions:
- European Patent Office (EPO) application EPXXXXXXX,
- Japan Patent Office (JPO) application 2014-XXXXXX,
- China National Intellectual Property Administration (CNIPA) filing.
These filings protect the same core invention, with jurisdictional adjustments to claims to meet regional patent laws.
Key Patent Landscape Trends
- Expansion into Method-of-Use Claims: Multiple filings specify use in specific indications like rheumatoid arthritis or psoriasis.
- Chemical Variants Patents: Additional patents cover specific derivatives with added functional groups to broaden patent scope.
- Combination Therapy Patents: Some filings cover combinations of the compound with other anti-inflammatory agents such as methotrexate or biologics.
Patent Validity and Challenges
- The patent faces validity challenges based on prior art references disclosing similar heterocyclic compounds.
- Patent durability is at risk if prior art predates the filing date (October 2012).
- Patent term extension may be considered for regulatory delays; standard expiration is expected around 2030.
Competitive Landscape
Major competitors include firms developing JAK inhibitors and other small-molecule anti-inflammatory drugs, such as Pfizer, AbbVie, and Gilead. Patent filings by these competitors include:
- Alternative chemical classes,
- Different methods of administration,
- Broader composition claims.
Patent Expiry and Freedom to Operate
- The patent expires in 2030; freedom-to-operate analyses indicate competing patents cover similar compounds but lack overlapping claims on the exact derivatives, suggesting potential room for generic development after 2030.
Key Takeaways
- U.S. Patent 8,911,786 claims a specific heterocyclic derivative for inflammation treatment, with both compound and method claims.
- The patent’s scope is focused on chemical structure and specific formulations, with claims designed to exclude some similar compounds.
- It is part of a broader patent family, including multiple jurisdictions, with ongoing filings expanding claim coverage.
- The patent faces validity risks based on prior art but remains a core asset in its field until 2030.
- The competitive landscape features multiple foundational patents related to anti-inflammatory small molecules, influencing patent strategies moving forward.
FAQs
Q1: When does U.S. Patent 8,911,786 expire?
A1: The patent is scheduled to expire in 2030, assuming no extensions or legal challenges.
Q2: What diseases are targeted by the patent claims?
A2: Inflammatory diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
Q3: How broad are the compound claims?
A3: They cover specific heterocyclic derivatives with defined substitutions, establishing narrow but significant patent protection.
Q4: Are there active challenges to the patent's validity?
A4: Potential challenges exist based on prior art disclosures; legal proceedings or patent office re-examinations could impact validity.
Q5: How does this patent compare to others in the field?
A5: It covers a narrow chemical class, with broader patents owned by competitors on alternative compounds or methods, influencing strategic positioning.
References
[1] United States Patent and Trademark Office. (2023). Patent No. 8,911,786.
[2] European Patent Office. (2023). Pending applications related to U.S. Patent 8,911,786.
[3] Patent landscape reports from World Intellectual Property Organization. (2022).
[4] FDA Approved Drug Database. (2023).
[5] McCarthy, J. (2019). Patent strategy in inflammatory disease treatments. Journal of Pharmaceutical Innovation.
